Cabot (CBT)
(Delayed Data from NYSE)
$104.24 USD
+2.86 (2.82%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $104.35 +0.11 (0.11%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
CBT 104.24 +2.86(2.82%)
Will CBT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CBT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CBT
Zacks.com featured highlights Leidos, Trane, Cabot, Vertiv and Charles River
5 Dividend Growth Stocks to Boost Your Portfolio
CBT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Cabot (CBT) is a Strong Value Stock
Here's Why Cabot (CBT) is a Strong Value Stock
3 Reasons Why Growth Investors Shouldn't Overlook Cabot (CBT)
Other News for CBT
Dividend Champion, Contender, And Challenger Highlights: Week Of August 25
Cabot Corp (CBT) Q3 2024 Earnings Call Transcript Highlights: Strong EPS Growth and Robust Cash Flow
Dow Up Over 450 Points As Big Tech Stocks Bounce
Cabot rises 16.3%
Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday